File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes

TitleSerum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes
Authors
KeywordsDPP4 inhibitor
FIB-4
NFS
SGLT2 inhibitor
Issue Date21-Dec-2023
PublisherWiley
Citation
Clinical Endocrinology, 2023 How to Cite?
Abstract

Objective: Baseline circulating thrombospondin-2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient elastography.

Design: Serum TSP2 levels were measured in participants from a randomized, open-label intervention study, at baseline and after 24-weeks treatment of either dapagliflozin 10 mg (N = 30) or sitagliptin 100 mg daily (N = 30). Vibration-controlled transient elastography was performed to evaluate the severity of hepatic fibrosis and steatosis using LS and controlled attenuation parameter (CAP), respectively.

Patients and measurements: Among all 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.8 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (p = .012), CAP (p = .015) and LS (p = .011) after 24 weeks.

Results: Serum TSP2 level decreased significantly from baseline in dapagliflozin-treated participants (p = .035), whereas no significant change was observed with sitagliptin. In correlation analysis, change in serum TSP2 levels only positively correlated with change in LS (r = .487, p = .006), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment.

Conclusions: Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.


Persistent Identifierhttp://hdl.handle.net/10722/339705
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.978
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMak, Jimmy Ho Cheung-
dc.contributor.authorLui, David Tak-Wai-
dc.contributor.authorFong, Carol Ho-Yi-
dc.contributor.authorCheung, Chloe Yu-Yan-
dc.contributor.authorWong, Ying-
dc.contributor.authorLee, Alan Chun-Hong-
dc.contributor.authorHoo, Ruby Lai-Chong-
dc.contributor.authorXu, Aimin-
dc.contributor.authorTan, Kathryn Choon-Beng-
dc.contributor.authorLam, Karen Siu-Ling-
dc.contributor.authorLee, Chi-Ho-
dc.date.accessioned2024-03-11T10:38:43Z-
dc.date.available2024-03-11T10:38:43Z-
dc.date.issued2023-12-21-
dc.identifier.citationClinical Endocrinology, 2023-
dc.identifier.issn0300-0664-
dc.identifier.urihttp://hdl.handle.net/10722/339705-
dc.description.abstract<p><strong>Objective: </strong>Baseline circulating thrombospondin-2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient elastography.</p><p><strong>Design: </strong>Serum TSP2 levels were measured in participants from a randomized, open-label intervention study, at baseline and after 24-weeks treatment of either dapagliflozin 10 mg (N = 30) or sitagliptin 100 mg daily (N = 30). Vibration-controlled transient elastography was performed to evaluate the severity of hepatic fibrosis and steatosis using LS and controlled attenuation parameter (CAP), respectively.</p><p><strong>Patients and measurements: </strong>Among all 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.8 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (p = .012), CAP (p = .015) and LS (p = .011) after 24 weeks.</p><p><strong>Results: </strong>Serum TSP2 level decreased significantly from baseline in dapagliflozin-treated participants (p = .035), whereas no significant change was observed with sitagliptin. In correlation analysis, change in serum TSP2 levels only positively correlated with change in LS (r = .487, p = .006), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment.</p><p><strong>Conclusions: </strong>Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.</p>-
dc.languageeng-
dc.publisherWiley-
dc.relation.ispartofClinical Endocrinology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectDPP4 inhibitor-
dc.subjectFIB-4-
dc.subjectNFS-
dc.subjectSGLT2 inhibitor-
dc.titleSerum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes-
dc.typeArticle-
dc.identifier.doi10.1111/cen.15010-
dc.identifier.pmid38127469-
dc.identifier.scopuseid_2-s2.0-85180506020-
dc.identifier.eissn1365-2265-
dc.identifier.isiWOS:001129465800001-
dc.identifier.issnl0300-0664-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats